Information Provided By: 
Fly News Breaks for May 23, 2019
KIN
May 23, 2019 | 07:32 EDT
Guggenheim analyst David Westenberg initiated coverage on 10 companies in animal health, starting Kindred Biosciences with a Buy rating and $11 price target. He sees risks of the company not meeting 2019-2021 consensus revenue numbers, but is constructive long-term because of its strong feline products and his view that Kindred has the deepest pipeline among small biotech companies. While "risky," he sees Kindred having meaningful potential upside, Westenberg said.
News For KIN From the Last 2 Days
There are no results for your query KIN
